CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 237 enrolled
Drug / intervention
OPC-1085EL ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02105272
NCT02105272Phase 3Completed
CompareCT.gov

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Apr 7, 2014·Updated Dec 21, 2015

In Brief

A Phase 3 clinical trial evaluating OPC-1085EL ophthalmic solution and Latanoprost ophthalmic solution for Glaucoma and Ocular Hypertension. Completed, enrolled 237 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with latanoprost ophthalmic solution in subjects who are insufficiently responsive to latanoprost ophthalmic solution.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 7, 2014
Enrollment StartApr 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.2 years ago

Interventions

OPC-1085EL ophthalmic solutiondrug

Latanoprost ophthalmic solutiondrug